These one-time payments completed our financial obligations associated with Emrosi's regulatory fees, and development milestones in the United States for the rosacea indication. As a result ...

These onetime payments completed our financial obligations associated with Emrosi's regulatory fees and development milestones in the United States for the rosacea indication. As a result ...

Treatment.com AI Inc. ("Treatment") is pleased to announce, further to its news release of February 12, 2025, that it has closed the acquisition of 100% of the issued and outstanding securities of ...

LAVAL, Quebec--(BUSINESS WIRE)-- Crescita Therapeutics Inc. (TSX ... New Distribution Agreement with IPG Pharmaceuticals Inc. for Pliaglis in the United States In December, we entered into an ...

Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR). Over the next few years, therapeutic companies, which develop a wide variety of treatments for ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

United Therapeutics (UTHR) announced that ten posters and presentations across its commercial and development portfolio will be presented at ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on United Therapeutics (UTHR – Research ...

United Therapeutics has a 12-month low of $221.53 and a 12-month high of $417.82. The business’s fifty day moving average price is $349.12 and its 200 day moving average price is $358.27.